Compare Norfolk Southern Corporation (NSC) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norfolk Southern Corporation vs BIO-TECHNE Corp — how do they compare? Norfolk Southern Corporation trades at $323.3 (market cap $73.65B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: Norfolk Southern Corporation is far larger — about 6.5× BIO-TECHNE Corp's market cap, and Norfolk Southern Corporation pays the higher dividend (1.65%). Which is the better fit depends on your goals.
| NSC | TECH | |
|---|---|---|
Market Cap | $73.65B | $11.34B |
Sector | Technology | Health |
52-Week High | $352.98 | $72.48 |
52-Week Low | $272.36 | $43.31 |
Enterprise Value | $89.20B | $11.36B |
Dividend Yield | 1.65% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norfolk Southern (NSC) trades at $327.92, down 0.47% on the day, amid a bearish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Key fundamentals show strong profitability with a 21.02% net income margin and 16.97% ROE, though valuation multiples like the P/E of 27.98 appear elevated. Recent news highlights ongoing institutional accumulation and progress in the proposed merger with Union Pacific, which remains under regulatory review.
The outlook is balanced; the merger potential offers upside, but regulatory hurdles and a premium valuation pose risks. Analyst consensus is mixed with a Hold rating predominating, though the $369.67 price target implies modest upside. Earnings sustainability and merger approval are critical for near-term direction.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
